Clinical Trials
430 trialsCINC424A2X01B Rollover Protocol
Novartis
Therapeutic RSK1 Targeting in Myelofibrosis
Washington University School of Medicine
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Vanderbilt-Ingram Cancer Center
Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
Université Catholique de Louvain
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Disc Medicine, Inc
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
National Cancer Institute (NCI)
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Bristol-Myers Squibb
Study of Canakinumab in Patients With Myelofibrosis
Icahn School of Medicine at Mount Sinai
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Icahn School of Medicine at Mount Sinai
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
MoTD
University of Birmingham
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
PACRIMYEL
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Ohio State University Comprehensive Cancer Center
Extended Access of Momelotinib in Adults With Myelofibrosis
GlaxoSmithKline
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Nanfang Hospital, Southern Medical University
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
Eilean Therapeutics
Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers
Eilean Therapeutics
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
SENTRY
Karyopharm Therapeutics Inc
ENERGIA
University of Turin, Italy
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Ohio State University Comprehensive Cancer Center
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
SICP RCT
University of Rochester
MK-3543-017
Merck Sharp & Dohme LLC
LIMBER
Incyte Corporation
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
University of Southern California
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
TRANSFORM-1
AbbVie
AVAJAK
University Hospital, Brest
ACCELERATE
Center for International Blood and Marrow Transplant Research
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
University of California, Irvine
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
BMT
Massachusetts General Hospital
CALRSUIVI
University Hospital, Angers
KEAP
Karyopharm Therapeutics Inc
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center